Ziv Gan-Or

List of Publications by Citations

165 papers	5,872 citations	34 h-index	74 g-index
203 ext. papers	8,366 ext. citations	6.9 avg, IF	5.37 L-index

#	Paper	IF	Citations
165	Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. *New England Journal of Medicine*, **2009**, 361, 1651-61	59.2	1351
164	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurology, The*, **2019**, 18, 1091-1102	24.1	562
163	Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. *Brain*, **2019**, 142, 744-759	11.2	303
162	Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. *Neurology*, **2008**, 70, 2277-83	6.5	259
161	Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. *Brain*, **2015**, 138, 2648-58	11.2	234
160	Differential effects of severe vs mild GBA mutations on Parkinson disease. *Neurology*, **2015**, 84, 880-7	6.5	198
159	Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease. *Autophagy*, **2015**, 11, 1443-57	10.2	168
158	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. *Neurology*, **2019**, 92, 329-337	6.5	144
157	Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and □synuclein mechanisms. *Movement Disorders*, **2019**, 34, 866-875	7	136
156	Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis. *Lancet Neurology, The*, **2017**, 16, 898-907	24.1	121
155	The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. *Neurology*, **2013**, 80, 1606-10	6.5	113
154	GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder. *Annals of Clinical and Translational Neurology*, **2015**, 2, 941-5	5.3	95
153	Mutations in CAPN1 Cause Autosomal-Recessive Hereditary Spastic Paraplegia. *American Journal of Human Genetics*, **2016**, 98, 1038-1046	11	70
152	Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. *Brain*, **2020**, 143, 234-248	11.2	69
151	Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?. *Neurology*, **2020**, 94, 481-494	6.5	60
150	LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease. *Neurogenetics*, **2010**, 11, 121-5	3	57
149	GBA-Associated Parkinson's Disease and Other Synucleinopathies. *Current Neurology and Neuroscience Reports*, **2018**, 18, 44	6.6	55

148	Clinical and genetic study of hereditary spastic paraplegia in Canada. *Neurology: Genetics*, **2017**, 3, e122	3.8	54
147	GBA p.T369M substitution in Parkinson disease: Polymorphism or association? A meta-analysis. *Neurology: Genetics*, **2016**, 2, e104	3.8	51
146	Parkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene. *Parkinsonism and Related Disorders*, **2018**, 55, 45-49	3.6	51
145	Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease. *JAMA Neurology*, **2018**, 75, 1416-1422	17.2	50
144	Association of sequence alterations in the putative promoter of RAB7L1 with a reduced parkinson disease risk. *Archives of Neurology*, **2012**, 69, 105-10		48
143	Differential phenotype in Parkinson's disease patients with severe versus mild GBA mutations. *Brain*, **2009**, 132, e125	11.2	42
142	SMPD1 mutations, activity, and α-synuclein accumulation in Parkinson's disease. *Movement Disorders*, **2019**, 34, 526-535	7	41
141	Replication study of MATR3 in familial and sporadic amyotrophic lateral sclerosis. *Neurobiology of Aging*, **2016**, 37, 209.e17-209.e21	5.6	41
140	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. *Movement Disorders*, **2019**, 34, 460-468	7	40
139	The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews. *Journal of Neural Transmission*, **2009**, 116, 1473-82	4.3	40
138	Genetic, Structural, and Functional Evidence Link TMEM175 to Synucleinopathies. *Annals of Neurology*, **2020**, 87, 139-153	9.4	40
137	Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics. *Parkinsonism and Related Disorders*, **2020**, 73, 60-71	3.6	40
136	Parkinson's Disease Genetic Loci in Rapid Eye Movement Sleep Behavior Disorder. *Journal of Molecular Neuroscience*, **2015**, 56, 617-22	3.3	38
135	RNF213 Is Associated with Intracranial Aneurysms in the French-Canadian Population. *American Journal of Human Genetics*, **2016**, 99, 1072-1085	11	38
134	Alpha galactosidase A activity in Parkinson's disease. *Neurobiology of Disease*, **2018**, 112, 85-90	7.5	37
133	Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations. *Parkinsonism and Related Disorders*, **2019**, 62, 179-184	3.6	37
132	The landscape of Parkin variants reveals pathogenic mechanisms and therapeutic targets in Parkinson's disease. *Human Molecular Genetics*, **2019**, 28, 2811-2825	5.6	35
131	Analysis of DNAJC13 mutations in French-Canadian/French cohort of Parkinson's disease. *Neurobiology of Aging*, **2016**, 45, 212.e13-212.e17	5.6	31

130	Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease. *European Journal of Medical Genetics*, **2019**, 62, 65-69	2.6	31
129	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. *Nature Genetics*, **2021**, 53, 294-303	36.3	31
128	The Parkinson's Disease Mendelian Randomization Research Portal. *Movement Disorders*, **2019**, 34, 1864-1872	7	29
127	A homozygous mutation in SLC1A4 in siblings with severe intellectual disability and microcephaly. *Clinical Genetics*, **2015**, 88, e1-4	4	27
126	The emerging role of SMPD1 mutations in Parkinson's disease: Implications for future studies. *Parkinsonism and Related Disorders*, **2015**, 21, 1294-5	3.6	26
125	Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression. *Movement Disorders* , **2021**, 36, 1420-1429	7	25
124	Fine-Mapping of SNCA in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies. *Annals of Neurology*, **2020**, 87, 584-598	9.4	24
123	Sleep disorders and Parkinson disease; lessons from genetics. *Sleep Medicine Reviews*, **2018**, 41, 101-112	10.2	24
122	De novo FUS P525L mutation in Juvenile amyotrophic lateral sclerosis with dysphonia and diplopia. *Neurology: Genetics*, **2016**, 2, e63	3.8	24
121	Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease. *Neurobiology of Aging*, **2018**, 64, 159.e5-159.e8	5.6	23
120	LRRK2 mutations in Parkinson disease; a sex effect or lack thereof? A meta-analysis. *Parkinsonism and Related Disorders*, **2015**, 21, 778-82	3.6	22
119	variants and glucocerebrosidase activity in Parkinson's disease. *Npj Parkinson's Disease*, **2016**, 2,	9.7	22
118	The age at motor symptoms onset in LRRK2-associated Parkinson's disease is affected by a variation in the MAPT locus: a possible interaction. *Journal of Molecular Neuroscience*, **2012**, 46, 541-4	3.3	22
117	Genetic and Clinical Predictors of Deep Brain Stimulation in Young-Onset Parkinson's Disease. *Movement Disorders Clinical Practice*, **2016**, 3, 465-471	2.2	21
116	Truncating Mutations in UBAP1 Cause Hereditary Spastic Paraplegia. *American Journal of Human Genetics*, **2019**, 104, 767-773	11	20
115	The dementia-associated APOE ε4 allele is not associated with rapid eye movement sleep behavior disorder. *Neurobiology of Aging*, **2017**, 49, 218.e13-218.e15	5.6	20
114	Glucocerebrosidase mutations and phenoconversion of REM sleep behavior disorder to parkinsonism and dementia. *Parkinsonism and Related Disorders*, **2019**, 65, 230-233	3.6	19
113	Large-scale pathway specific polygenic risk and transcriptomic community network analysis identifies novel functional pathways in Parkinson disease. *Acta Neuropathologica*, **2020**, 140, 341-358	14.3	19

112	Longstanding disease-free survival in idiopathic REM sleep behavior disorder: Is neurodegeneration inevitable?. *Parkinsonism and Related Disorders*, **2018**, 54, 99-102	3.6	19
111	Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson's disease. *Journal of Medical Genetics*, **2020**, 57, 331-338	5.8	19
110	Full sequencing and haplotype analysis of MAPT in Parkinson's disease and rapid eye movement sleep behavior disorder. *Movement Disorders*, **2018**, 33, 1016-1020	7	19
109	Biomarkers of conversion to □synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. *Lancet Neurology, The*, **2021**, 20, 671-684	24.1	19
108	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. *Movement Disorders*, **2019**, 34, 1851-1863	7	18
107	variants in REM sleep behavior disorder: A multicenter study. *Neurology*, **2020**, 95, e1008-e1016	6.5	18
106	The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository. *Journal of Parkinson's Disease*, **2020**, 10, 301-313	5.3	17
105	Comprehensive assessment of PINK1 variants in Parkinson's disease. *Neurobiology of Aging*, **2020**, 91, 168.e1-168.e5	5.6	17
104	Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets. *JAMA Neurology*, **2021**, 78, 464-472	17.2	17
103	Genetic markers of Restless Legs Syndrome in Parkinson disease. *Parkinsonism and Related Disorders*, **2015**, 21, 582-5	3.6	16
102	LRRK2 protective haplotype and full sequencing study in REM sleep behavior disorder. *Parkinsonism and Related Disorders*, **2018**, 52, 98-101	3.6	16
101	Down-regulation of B cell-related genes in peripheral blood leukocytes of Parkinson's disease patients with and without GBA mutations. *Molecular Genetics and Metabolism*, **2016**, 117, 179-85	3.7	15
100	Common and rare GCH1 variants are associated with Parkinson's´disease. *Neurobiology of Aging*, **2019**, 73, 231.e1-231.e6	5.6	15
99	Analysis of functional GLO1 variants in the BTBD9 locus and restless legs syndrome. *Sleep Medicine*, **2015**, 16, 1151-5	4.6	14
98	The Alzheimer disease BIN1 locus as a modifier of GBA-associated Parkinson disease. *Journal of Neurology*, **2015**, 262, 2443-7	5.5	14
97	POLR3A variants in hereditary spastic paraplegia and ataxia. *Brain*, **2018**, 141, e1	11.2	14
96	CAPN1 mutations: Expanding the CAPN1-related phenotype: From hereditary spastic paraparesis to spastic ataxia. *European Journal of Medical Genetics*, **2019**, 62, 103605	2.6	13
95	Analysis of common and rare variants in late-onset Parkinson disease. *Neurology: Genetics*, **2020**, 6, 385	3.8	13

94	Homozygosity for the MTX1 c.184T>A (p.S63T) alteration modifies the age of onset in GBA-associated Parkinson's disease. *Neurogenetics*, **2011**, 12, 325-32	3	12
93	Sequencing of the GBA coactivator, Saposin C, in Parkinson disease. *Neurobiology of Aging*, **2018**, 72, 187.e1-187.e3	5.6	12
92	Clinical and genetic analysis of ATP13A2 in hereditary spastic paraplegia expands the phenotype. *Molecular Genetics & Genomic Medicine*, **2020**, 8, e1052	2.3	11
91	Analysis of Heterozygous PRKN Variants and Copy-Number Variations in Parkinson's Disease. *Movement Disorders*, **2021**, 36, 178-187	7	11
90	Targeted sequencing of Parkinson's disease loci genes highlights SYT11, FGF20 and other associations. *Brain*, **2021**, 144, 462-472	11.2	11
89	Genome-wide association analysis identifies new candidate risk loci for familial intracranial aneurysm in the French-Canadian population. *Scientific Reports*, **2018**, 8, 4356	4.9	10
88	Tandem mass spectrometry assay of β-glucocerebrosidase activity in dried blood spots eliminates false positives detected in fluorescence assay. *Molecular Genetics and Metabolism*, **2018**, 123, 135-139	3.7	10
87	Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. *Annals of Clinical and Translational Neurology*, **2020**, 7, 1816-1830	5.3	10
86	Heritability Enrichment Implicates Microglia in Parkinson's Disease Pathogenesis. *Annals of Neurology*, **2021**, 89, 942-951	9.4	10
85	The role of the melanoma gene MC1R in Parkinson disease and REM sleep behavior disorder. *Neurobiology of Aging*, **2016**, 43, 180.e7-180.e13	5.6	10
84	Triple A syndrome presenting as complicated hereditary spastic paraplegia. *Molecular Genetics & Genomic Medicine*, **2018**, 6, 1134-1139	2.3	10
83	ARSA variants in α-synucleinopathies. *Brain*, **2019**, 142, e70	11.2	9
82	CHRNB3 c.-57A>G functional promoter change affects Parkinson's disease and smoking. *Neurobiology of Aging*, **2014**, 35, 2179.e1-6	5.6	9
81	SEPT14 Is Associated with a Reduced Risk for Parkinson's Disease and Expressed in Human Brain. *Journal of Molecular Neuroscience*, **2016**, 59, 343-50	3.3	9
80	Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson's disease. *Neurobiology of Aging*, **2021**, 97, 148.e17-148.e24	5.6	9
79	Association study of essential tremor genetic loci in Parkinson's disease. *Neurobiology of Aging*, **2018**, 66, 178.e13-178.e15	5.6	8
78	False-positive results using a Gaucher diagnostic kit--RecTL and N370S. *Molecular Genetics and Metabolism*, **2010**, 100, 100-2	3.7	8
77	Enrichment of alleles encoding variants with constitutively hyperactive NADase in patients with ALS and other motor nerve disorders. *ELife*, **2021**, 10,	8.9	8

76	Association study of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's disease. *Neurobiology of Aging*, **2021**, 100, 119.e7-119.e13	5.6	8
75	Variants in the Niemann-Pick type C gene NPC1 are not associated with Parkinson's disease. *Neurobiology of Aging*, **2020**, 93, 143.e1-143.e4	5.6	7
74	TOX3 Variants Are Involved in Restless Legs Syndrome and Parkinson's Disease with Opposite Effects. *Journal of Molecular Neuroscience*, **2018**, 64, 341-345	3.3	7
73	The GBA p.Trp378Gly mutation is a probable French-Canadian founder mutation causing Gaucher disease and synucleinopathies. *Clinical Genetics*, **2018**, 94, 339-345	4	7
72	Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal. *Translational Neurodegeneration*, **2020**, 9, 39	10.3	7
71	Assessing non-Mendelian inheritance in inherited axonopathies. *Genetics in Medicine*, **2020**, 22, 2114-2118	8.1	7
70	Comprehensive Analysis of Familial Parkinsonism Genes in Rapid-Eye-Movement Sleep Behavior Disorder. *Movement Disorders*, **2021**, 36, 235-240	7	7
69	Evidence for Non-Mendelian Inheritance in Spastic Paraplegia 7. *Movement Disorders*, **2021**, 36, 1664-1675		7
68	SPTAN1 variants as a potential cause for autosomal recessive hereditary spastic paraplegia. *Journal of Human Genetics*, **2019**, 64, 1145-1151	4.3	6
67	Parkinson disease age of onset GWAS: defining heritability, genetic loci and a-synuclein mechanisms		6
66	GBA variation and susceptibility to multiple system atrophy. *Parkinsonism and Related Disorders*, **2020**, 77, 64-69	3.6	6
65	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. *Annals of Neurology*, **2021**, 90, 35-42	9.4	6
64	A 23 years follow-up study identifies GLUT1 deficiency syndrome initially diagnosed as complicated hereditary spastic paraplegia. *European Journal of Medical Genetics*, **2016**, 59, 564-568	2.6	6
63	Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease. *Movement Disorders*, **2021**, 36, 1451-1455	7	6
62	Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder. *Brain*, **2017**, 140, e32	11.2	5
61	Age at Onset of Parkinson's Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations. *Journal of Parkinson's Disease*, **2020**, 10, 1123-1132	5.3	5
60	Classification of GBA Variants and Their Effects in Synucleinopathies. *Movement Disorders*, **2019**, 34, 1581-1582	7	5
59	Common X-Chromosome Variants Are Associated with Parkinson Disease Risk. *Annals of Neurology*, **2021**, 90, 22-34	9.4	5

58	Fine mapping of the HLA locus in Parkinson's disease in Europeans. *Npj Parkinson's Disease*, **2021**, 7, 84	9.7	5
57	RIC3 variants are not associated with Parkinson's disease in French-Canadians and French. *Neurobiology of Aging*, **2017**, 53, 194.e9-194.e11	5.6	4
56	Calpain 1 in neurodegeneration: a therapeutic target?. *Lancet Neurology, The*, **2016**, 15, 1118	24.1	4
55	Exposure to Pesticides and Welding Hastens the Age-at-Onset of Parkinson's Disease. *Canadian Journal of Neurological Sciences*, **2019**, 46, 711-716	1	4
54	Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease. *Movement Disorders*, **2021**,	7	4
53	Genetic and epidemiological characterization of restless legs syndrome in Québec. *Sleep*, **2020**, 43,	1.1	4
52	Decreased Penetrance of Parkinson's Disease in Elderly Carriers of Glucocerebrosidase Gene L444P/R Mutations: A Community-Based 10-Year Longitudinal Study. *Movement Disorders*, **2020**, 35, 672-678	7	4
51	No genetic evidence for involvement of alcohol dehydrogenase genes in risk for Parkinson's disease. *Neurobiology of Aging*, **2020**, 87, 140.e19-140.e22	5.6	4
50	Screening of novel restless legs syndrome-associated genes in French-Canadian families. *Neurology: Genetics*, **2018**, 4, e296	3.8	4
49	Dynamics of microtubules and their associated proteins: Recent insights and clinical implications. *Neurology*, **2016**, 87, 2173	6.5	3
48	New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin. *Neuropharmacology*, **2022**, 202, 108822	5.5	3
47	Genetic Stratification of Age-Dependent Parkinson's Disease Risk by Polygenic Hazard Score. *Movement Disorders*, **2021**,	7	3
46	Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson's disease		3
45	Lack of evidence for genetic association of saposins A, B, C and D with Parkinson's disease. *Brain*, **2020**, 143, e72	11.2	3
44	GCH1 mutations in hereditary spastic paraplegia. *Clinical Genetics*, **2021**, 100, 51-58	4	3
43	Identification of sixteen novel candidate genes for late onset Parkinson's disease. *Molecular Neurodegeneration*, **2021**, 16, 35	19	3
42	LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease. *Neurobiology of Aging*, **2021**, 103, 142.e1-142.e5	5.6	3
41	Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk. *Movement Disorders*, **2021**,	7	3

40	Tau and MAPT genetics in tauopathies and synucleinopathies. *Parkinsonism and Related Disorders*, **2021**, 90, 142-154	3.6	3
39	Novel Associations of and With REM Sleep Behavior Disorder. *Neurology*, **2021**, 96, e1402-e1412	6.5	3
38	Brain atrophy progression in Parkinson's disease is shaped by connectivity and local vulnerability. *Brain Communications*, **2021**, 3, fcab269	4.5	2
37	Rare PSAP Variants and Possible Interaction with GBA in REM Sleep Behavior Disorder. *Journal of Parkinson's Disease*, **2021**,	5.3	2
36	No Evidence for a Causal Relationship Between Cancers and Parkinson's Disease. *Journal of Parkinson's Disease*, **2021**, 11, 801-809	5.3	2
35	Lack of evidence for association of UQCRC1 with Parkinson's disease in Europeans. *Neurobiology of Aging*, **2021**, 101, 297.e1-297.e4	5.6	2
34	De novo DHDDS variants cause a neurodevelopmental and neurodegenerative disorder with myoclonus. *Brain*, **2021**,	11.2	2
33	SORL1 mutation in a Greek family with Parkinson's disease and dementia. *Annals of Clinical and Translational Neurology*, **2021**, 8, 1961-1969	5.3	2
32	Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome.. *Nature Communications*, **2021**, 12, 7342	17.4	2
31	PARK16 haplotypes and the importance of protective genetic factors in Parkinson's disease. *Journal of Human Genetics*, **2015**, 60, 461-2	4.3	1
30	Reply to: No Evidence that Glucosylsphingosine Is a Biomarker for Parkinson Disease.. *Movement Disorders*, **2022**,	7	1
29	A comprehensive analysis of dominant and recessive parkinsonism genes in REM sleep behavior disorder		1
28	Heterozygous de novo KPNA3 Mutations Cause Complex Hereditary Spastic Paraplegia. *Annals of Neurology*, **2021**,	9.4	1
27	The commercial genetic testing landscape for Parkinson's disease. *Parkinsonism and Related Disorders*, **2021**, 92, 107-111	3.6	1
26	Targeted sequencing of Parkinson disease loci genes highlights SYT11, FGF20 and other associations		1
25	SMPD1 variants do not have a major role in rapid eye movement sleep behavior disorder. *Neurobiology of Aging*, **2020**, 93, 142.e5-142.e7	5.6	1
24	Large-scale pathway-specific polygenic risk, transcriptomic community networks and functional inferences in Parkinson disease		1
23	Analysis of heterozygous PRKN variants and copy number variations in Parkinson disease		1

22	LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson disease		1
21	Clinical and genetic analysis of Costa Rican patients with Parkinson disease		1
20	Fine mapping of the HLA locus in Parkinson disease in Europeans		1
19	17q21.31 sub-haplotypes underlying H1-associated risk for Parkinson disease are associated with LRRC37A/2 expression in astrocytes		1
18	Occurrence of Amyotrophic Lateral Sclerosis in Type 1 Gaucher Disease. *Neurology: Genetics*, **2021**, 7, e600	3.8	1
17	Genetics of REM Sleep Behavior Disorder **2019**, 589-609		1
16	Association of the CD2AP locus with cognitive functioning among middle-aged individuals with a family history of Alzheimer's disease. *Neurobiology of Aging*, **2021**, 101, 50-56	5.6	1
15	Replication assessment of NUS1 variants in Parkinson's disease. *Neurobiology of Aging*, **2021**, 101, 300.e1-300.e3	5.6	1
14	Synuclein (SNCA) A30G Mutation as a Cause of a Complex Phenotype Without Parkinsonism. *Movement Disorders*, **2021**, 36, 2209-2212	7	1
13	Genome-wide association study of REM sleep behavior disorder identifies novel loci with distinct polygenic and brain expression effects		1
12	Hereditary spastic paraplegia initially diagnosed as cerebral palsy. *Clinical Parkinsonism & Related Disorders*, **2021**, 5, 100114	0.9	0
11	Lack of Causal Effects or Genetic Correlation between Restless Legs Syndrome and Parkinson's Disease. *Movement Disorders*, **2021**, 36, 1967-1972	7	0
10	Analysis of PTRHD1 common and rare variants in European patients with Parkinson's disease. *Neurobiology of Aging*, **2021**, 107, 178-180	5.6	0
9	Genetic and Epidemiological Study of Adult Ataxia and Spastic Paraplegia in Eastern Quebec. *Canadian Journal of Neurological Sciences*, **2021**, 48, 655-665	1	0
8	Clinical and Genetic Analysis of Costa Rican Patients With Parkinson's Disease. *Frontiers in Neurology*, **2021**, 12, 656342	4.1	0
7	Genetic, structural and clinical analysis of spastic paraplegia 4.. *Parkinsonism and Related Disorders*, **2022**, 98, 62-69	3.6	0
6	Rapid eye movement sleep behaviour disorder: Past, present, and future.. *Journal of Sleep Research* , **2022**, e13612	5.8	0
5	KCNA2 mutations are rare in hereditary spastic paraplegia. *Annals of Neurology*, **2017**, 81, 325-326	9.4	

List of Publications

4	Common and rare variants in HFE are not associated with Parkinson's disease in Europeans. *Neurobiology of Aging*, **2021**, 107, 174-177	5.6
3	Case-Control and Family-Based Association Study of Specific Variants in Restless Legs Syndrome. *Movement Disorders Clinical Practice*, **2016**, 3, 460-464	2.2
2	Genetics of Non-Motor Symptoms of Parkinson's Disease **2022**, 199-211	
1	Transcriptome analysis highlights common pathways between Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 3, e050014	1.2